Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes

키워드

참고문헌 (75)

1. Sacco S, "Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry", Stroke, 40, pp.394~399 (2009)
2. Flaherty ML, "Anticoagulant-associated intracerebral hemorrhage", Semin Neurol, 30, pp.565~572 (2010)
3. Alotaibi GS, "Secular trends in incidence and mortality of acute venous thromboembolism: the AB-VTE population-based study", Am J Med, 129, pp.879~ (2016)
4. Writing Group Members, "Heart disease and stroke statistics-2016 update: a report from the American heart association", Circulation, 133, pp.e38~e360 (2016)
5. Steinberg BA, "International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBITAF II registries", Am Heart J, 194, pp.132~140 (2017)
6. Ruff CT, "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials", Lancet, 383, pp.955~962 (2014)
7. Yao X, "Effect of adherence to oral anticoagulants on risk of stroke and major bleeding among patients with atrial fibrillation", J Am Heart Assoc, 5, pp.e003074~ (2016)
8. Ruff CT, "Management of bleeding with non-vitamin K antagonist oral anticoagulants in the era of specific reversal agents", Circulation, 134, pp.248~261 (2016)
9. Epple C, "Acute stroke in patients on new direct oral anticoagulants: how to manage, how to treat", Expert Opin Pharmacother, 15, pp.1991~2001 (2014)
10. Eerenberg ES, "Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebocontrolled, crossover study in healthy subjects", Circulation, 124, pp.1573~1579 (2011)
11. Steiner T, "Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban", Clin Res Cardiol, 102, pp.399~412 (2013)
12. Tomaselli GF, "2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology task force on expert consensus decision pathways", J Am Coll Cardiol, 70, pp.3042~3067 (2017)
13. Levy JH, "When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH", J Thromb Haemost, 14, pp.623~627 (2016)
14. Cuker A, "Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants", J Am Coll Cardiol, 64, pp.1128~1139 (2014)
15. Samuelson BT, "Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review", Chest, 151, pp.127~138 (2017)
16. van Ryn J, "Dabigatran etexilate: a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity", Thromb Haemost, 103, pp.1116~1127 (2010)
17. Cuker A, "Laboratory measurement of the non-vitamin K antagonist oral anticoagulants: selecting the optimal assay based on drug, assay availability, and clinical indication", J Thromb Thrombolysis, 41, pp.241~247 (2016)
18. Samama MM, "Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls", Thromb Haemost, 107, pp.379~387 (2012)
19. Cuker A, "Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review", J Thromb Thrombolysis, 39, pp.288~294 (2015)
20. Rizos T, "Point-of-care international normalized ratio testing accelerates thrombolysis in patients with acute ischemic stroke using oral anticoagulants", Stroke, 40, pp.3547~3551 (2009)
21. Ebner M, "Point-of-care testing of coagulation in patients treated with non-vitamin K antagonist oral anticoagulants", Stroke, 46, pp.2741~2747 (2015)
22. van Ryn J, "Interpretation of point-ofcare INR results in patients treated with dabigatran", Am J Med, 125, pp.417~420 (2012)
23. Ebner M, "Point-of-care testing for emergency assessment of coagulation in patients treated with direct oral anticoagulants", Crit Care, 21, pp.32~ (2017)
24. Mani H, "Point-of-care coagulation testing for assessment of the pharmacodynamic anticoagulant effect of direct oral anticoagulant", Ther Drug Monit, 36, pp.624~631 (2014)
25. Eikelboom J, "Bleeding with direct oral anticoagulants vs warfarin: clinical experience", Am J Med, 129(11S), pp.S33~S40 (2016)
26. Katsanos AH, "Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis", Eur J Neurol, 25, pp.1299~1302 (2018)
27. Steiner T, "European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage", Int J Stroke, 9, pp.840~855 (2014)
28. Qureshi AI, "Intensive blood-pressure lowering in patients with acute cerebral hemorrhage", N Engl J Med, 375, pp.1033~1043 (2016)
29. Mendelow AD, "Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH II): a randomised trial", Lancet, 382, pp.397~408 (2013)
30. Mendelow AD, "Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial", Lancet, 365, pp.387~397 (2005)
31. Boulouis G, "Intensive blood pressure lowering in patients with acute intracerebral haemorrhage: clinical outcomes and haemorrhage expansion. Systematic review and meta-analysis of randomised trials", J Neurol Neurosurg Psychiatry, 88, pp.339~345 (2017)
32. Kuramatsu JB, "Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage", JAMA, 313, pp.824~836 (2015)
33. January CT, "2014 AHA", ACC, American Heart Association task force on practice guidelines and the Heart Rhythm Society, pp.J Am Coll Cardiol, 2014[DOI]
34. Schulman S, "Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients", J Thromb Haemost, 8, pp.202~204 (2010)
35. Flibotte JJ, "Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage", Neurology, 63, pp.1059~1064 (2004)
36. Hart RG, "Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses", Stroke, 26, pp.1471~1477 (1995)
37. Rosand J, "Warfarinassociated hemorrhage and cerebral amyloid angiopathy: a genetic and pathologic study", Neurology, 55, pp.947~951 (2000)
38. Purrucker JC, "Early clinical and radiological course, management, and outcome of intracerebral hemorrhage related to new oral anticoagulants", JAMA Neurol, 73, pp.169~177 (2016)
39. Tsivgoulis G, "Direct oral anticoagulant- vs vitamin K antagonist-related nontraumatic intracerebral hemorrhage", Neurology, 89, pp.1142~1151 (2017)
40. Inohara T, "Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality", JAMA, 319, pp.463~473 (2018)
41. Pollack CV Jr, "Idarucizumab for Dabigatran Reversal", N Engl J Med, 373, pp.511~520 (2015)
42. Pollack CV Jr, "Idarucizumab for dabigatran reversal: full cohort analysis", N Engl J Med, 377, pp.431~441 (2017)
43. Kermer P, "Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany: a national case collection", Int J Stroke, 12, pp.383~391 (2017)
44. Marlu R, "Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a andomized crossover ex vivo study in healthy volunteers", Thromb Haemost, 108, pp.217~224 (2012)
45. Zhou W, "Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran", Stroke, 42, pp.3594~3599 (2011)
46. Frontera JA, "Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine", Neurocrit Care, 24, pp.6~46 (2016)
47. Siegal DM, "Andexanet alfa for the reversal of factor Xa inhibitor activity", N Engl J Med, 373, pp.2413~2424 (2015)
48. "Accelerated approval of Andexxa" (2018)[URL]
49. Lu G, "A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa", Nat Med, 19, pp.446~451 (2013)
50. Connolly SJ, "Andexanet alfa for acute major bleeding associated with factor Xa inhibitors", N Engl J Med, 375, pp.1131~1141 (2016)
51. Levi M, "Comparison of three-factor and fourfactor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers", J Thromb Haemost, 12, pp.1428~1436 (2014)
52. Gerner ST, "Association of prothrombin complex concentrate administration and hematoma enlargement in nonvitamin K antagonist oral anticoagulant-related intracerebral hemorrhage", Ann Neurol, 83, pp.186~196 (2018)
53. Barco S, "In vivo reversal of the anticoagulant effect of rivaroxaban with four-factor prothrombin complex concentrate", Br J Haematol, 172, pp.255~261 (2016)
54. Cheung YW, "In vivo increase in thrombin generation by fourfactor prothrombin complex concentrate in apixaban-treated healthy volunteers", J Thromb Haemost, 13, pp.1799~1805 (2015)
55. Zahir H, "Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate", Circulation, 131, pp.82~90 (2015)
56. Heidbuchel H, "Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary", Eur Heart J, 38, pp.2137~2149 (2017)
57. Dibu JR, "The role of FEIBA in reversing novel oral anticoagulants in intracerebral hemorrhage", Neurocrit Care, 24, pp.413~419 (2016)
58. Leissinger CA, "Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature", Am J Hematol, 83, pp.137~143 (2008)
59. Enriquez A, "Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants", Europace, 18, pp.955~964 (2016)
60. Ansell JE, "Use of PER977 to reverse the anticoagulant effect of edoxaban", N Engl J Med, 371, pp.2141~2142 (2014)
61. Ansell JE, "Single-dose ciraparantag safely and completely reverses anticoagulant effects of edoxaban", Thromb Haemost, 117, pp.238~245 (2017)
62. Sheffield WP, "<TEX>$\gamma$<", TEX>T-S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivo, 2014, pp.12, 1110~1115
63. Eckman MH, "Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis", Stroke, 34, pp.1710~1716 (2003)
64. Morgenstern LB, "Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2010, pp.41, 2108~2129
65. Steiner T, "Resumption of oral anticoagulation after warfarinassociated intracerebral hemorrhage: yes", Stroke, 42, pp.3661~3662 (2011)
66. Hernandez I, "Anticoagulation use and clinical outcomes after major bleeding on dabigatran or warfarin in atrial fibrillation", Stroke, 48, pp.159~166 (2017)
67. Molina CA, "The dilemma of resuming anticoagulation after intracranial hemorrhage: little evidence facing big fears", Stroke, 42, pp.3665~3666 (2011)
68. Paciaroni M, "Should oral anticoagulants be restarted after warfarin-associated cerebral haemorrhage in patients with atrial fibrillation?", Thromb Haemost, 111, pp.14~18 (2014)
69. Biffi A, "Oral anticoagulation and functional outcome after intracerebral hemorrhage", Ann Neurol, 82, pp.755~765 (2017)
70. Nielsen PB, "Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study", Circulation, 132, pp.517~525 (2015)
71. Purrucker JC, "Management of acute stroke in patients on oral anticoagulants", Curr Opin Neurol, 30, pp.1~7 (2017)
72. Horstmann S, "Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage", Neurology, 82, pp.135~138 (2014)
73. Sahay S, "Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials", Heart, 103, pp.139~147 (2017)
74. Reddy VY, "5-Year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials", J Am Coll Cardiol, 70, pp.2964~2975 (2017)
75. Hemphill JC 3rd, "Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association", American Stroke Association, 2015, pp.46, 2032~2060

관련 논문AI추천